G. Bolli

G. Bolli, 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Insulin: evolution of insulin formulations and their application in clinical practice over 100 years

D. Owens, G. Bolli, A. Cheng, 2022, Acta Diabetologica.

Reply to Bastyr et al.

G. Bolli, E. Torlone, 1997, Diabetes Care.

Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects

P. Lucidi, P. Rossetti, F. Porcellati, 2011, Diabetes Care.

of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects A randomized cross-over study

P. Lucidi, A. Andreoli, G. Bolli, 2011 .

Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH , Glargine , and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetes

P. Rossetti, F. Porcellati, P. Candeloro, 2011 .

Importance of catecholamines in defense against insulin hypoglycemia in humans.

G. Bolli, 1998, Advances in pharmacology.

Treatment of Diabetes with L363,586

G. Bolli, J. Gerich, P. Campbell, 1987 .

Establishing the deficiency of glucagon response to hypoglycemia in humans.

G. Bolli, 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Urinary excretion and plasma levels of norepinephrine and epinephrine during diabetic ketoacidosis

P. Brunetti, G. Bolli, F. Santeusanio, 1979, Acta diabetologia latina.

Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia.

P. Lucidi, G. Bolli, C. Fanelli, 2002, Diabetes.

A Review of its Therapeutic Use as a Long-Acting Agent for the Management of Type 1 and 2 Diabetes Mellitus

L. Heinemann, H. Yki-Järvinen, G. Bolli, 2001 .

Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136

P. Lucidi, F. Porcellati, G. Bolli, 2021, Diabetes Care.

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus

P. Lucidi, P. Rossetti, F. Porcellati, 2011, Diabetes Care.

Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus

F. Porcellati, A. Andreoli, G. Bolli, 2011 .

Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial

J. Rosenstock, D. Müller-Wieland, J. Westerbacka, 2020, Diabetes, obesity & metabolism.

Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.

A. Tiengo, A. Consoli, B. Charbonnel, 2004, Clinical therapeutics.

Comparison of a Multiple Daily Insulin Injection Regime (Basal Once-Daily Glargine plus Mealtime Lispro) and CSII (Lispro) in Type 1 Diabetes: a Randomized Open Parallel Multicenter Study

P. Home, G. Bolli, E. Torlone, 2009 .

Pump Insulin Pump T Tr r eatment in eatment in T T ype 2 Diabetes ype 2 Diabetes

D. Owens, E. Renard, M. Massi-Benedetti, 2008 .

Rationale for using combinations of short-acting insulin analogue and NPH insulin at mealtime in the treatment of type 1 diabetes mellitus.

G. Bolli, 1999, Journal of pediatric endocrinology & metabolism : JPEM.

Gamma-glutamyltransferase, arterial remodeling and prehypertension in a healthy population at low cardiometabolic risk

M. Laakso, O. Melander, B. Balkau, 2020, Journal of Human Hypertension.

Unawareness of hypoglycemia.

G. Bolli, C. Fanelli, 1995, The New England journal of medicine.

Effects of the Short-Acting Insulin Analog [Lys(B28),Pro(B29)] on Postprandial Blood Glucose Control in IDDM

P. Brunetti, S. Pampanelli, G. Perriello, 1996, Diabetes Care.

Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.

Ronan Roussel, Timothy S. Bailey, T. Bailey, 2017, Diabetes & metabolism.

C‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective

B. Frier, R. Little, G. Bolli, 2022, Diabetes, obesity & metabolism.

Basal‐bolus insulin therapy in Type 1 diabetes: comparative study of pre‐meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin

B. Frier, G. Bolli, M. Herz, 2002, Diabetic medicine : a journal of the British Diabetic Association.

Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations.

E. Ghigo, P. Lucidi, G. Bolli, 2005, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Assessment of the level of Assessment of the level

D. Owens, E. Renard, M. Massi-Benedetti, 2007 .

Improved glycemic control can be better maintained with insulin lispro than with human regular insulin

P. Jansson, R. Gomis, I. Conget, 1998 .

Improved Postprandial Metabolic Control After Subcutaneous Injection of a Short-Acting Insulin Analog in IDDM of Short Duration With Residual Pancreatic β-Cell Function

P. Brunetti, S. Pampanelli, G. Bolli, 1995, Diabetes Care.

How to ameliorate the problem of hypoglycemia in intensive as well as nonintensive treatment of type 1 diabetes.

G. Bolli, 1999, Diabetes care.

GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials.

P. Lucidi, F. Porcellati, G. Bolli, 2015, Diabetes & metabolism.

Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH‐based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‐nations trial

D. Bruttomesso, R. Gomis, G. Bolli, 2006, Diabetic medicine : a journal of the British Diabetic Association.

Reply to DeVries

D. Owens, G. Bolli, 2009 .

Red cell 2,3-DPG levels in diabetic vasculopathy

M. Massi-Benedetti, P. Brunetti, G. Calabrese, 1979, Acta diabetologia latina.

New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in a Meta-Analysis of Phase 3a EDITION Clinical Trials in People with T2DM

I. Hramiak, R. Roussel, H. Yki-Järvinen, 2014 .

Effect of Oral Amino Acids on Counterregulatory Responses and Cognitive Function During Insulin-Induced Hypoglycemia in Nondiabetic and Type 1 Diabetic People

K. Nair, P. Rossetti, F. Porcellati, 2008, Diabetes.

Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes

D. Owens, P. Lucidi, P. Rossetti, 2007, Diabetes Care.

Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes

P. Home, G. Bolli, E. Torlone, 2009, Diabetes Care.

Early insulin treatment in type 2 diabetes: ORIGINal sin or valuable choice as ORIGINal treatment? An open debate on the ORIGIN study results.

A. Consoli, G. Bolli, A. Giaccari, 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Alternative routes of insulin delivery

B. Zinman, D. Owens, G. Bolli, 2003, Diabetic medicine : a journal of the British Diabetic Association.

Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus.

Emanuela Falcinelli, Paolo Gresele, Carlo Lalli, 2003, Journal of the American College of Cardiology.

Insulin is required for prandial ghrelin suppression in humans.

P. Lucidi, G. Bolli, C. Fanelli, 2003, Diabetes.

Blood glucose concentrations and breast cancer risk in women without diabetes: a meta-analysis

P. Boyle, J. Rosenstock, P. Autier, 2013, European Journal of Nutrition.

Physiological Increments in Plasma Insulin Concentrations Have Selective and Different Effects on Synthesis of Hepatic Proteins in Normal Humans

G. Cruciani, E. Mannarino, E. Volpi, 1993, Diabetes.

Effects of whole-body vibration exercise on the endocrine system of healthy men

C. Bosco, P. Lucidi, G. Bolli, 2004, Journal of endocrinological investigation.

Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes

T. Heise, R. Becker, G. Bolli, 2012, Diabetes Care.

Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era.

P. Lucidi, A. Andreoli, G. Bolli, 2011, Diabetes technology & therapeutics.

Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response study.

P. Lucidi, F. Porcellati, P. Candeloro, 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial

P. Home, G. Bolli, W. Landgraf, 2020, Diabetes, obesity & metabolism.

Fasting C‐peptide, a biomarker for hypoglycaemia risk in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL

D. Owens, B. Frier, G. Bolli, 2019, Diabetes, obesity & metabolism.

Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.

M. Songini, G. Riccardi, S. Del Prato, 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Sulphonylureas and pregnancy.

G. Bolli, C. Fanelli, 1998, European journal of endocrinology.

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes

C. Mathieu, M. Riddle, G. Bolli, 2014, Diabetes, obesity & metabolism.

Prevention of Hypoglycemia While Achieving Good Glycemic Control in Type 1 Diabetes

P. Rossetti, F. Porcellati, G. Bolli, 2008, Diabetes Care.

Contribution of Autonomic Neuropathy to Reduced Plasma Adrenaline Responses to Hypoglycemia in IDDM: Evidence for a Nonselective Defect

P. Brunetti, S. Pampanelli, G. Bolli, 1997, Diabetes.

Abnormal Glucose Counterregulation in Insulin-dependent Diabetes Mellitus: Interaction of Anti-Insulin Antibodies and Impaired Glucagon and Epinephrine Secretion

P. Brunetti, G. Bolli, J. Gerich, 1983, Diabetes.

Diabetes and breast cancer risk: a meta-analysis

M Smans, P. Boyle, J. Rosenstock, 2012, British Journal of Cancer.

35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts.

Thomas J. Smith, B. M. Rasmussen, V. C. Phan, 1999, Diabetologia.

Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension).

M. Matsuhisa, M. Riddle, G. Bolli, 2016, Diabetes research and clinical practice.

Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%

D. Owens, B. Frier, P. Home, 2019, Diabetes, obesity & metabolism.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

R. Bergenstal, P. Home, M. Riddle, 2015, Diabetes Care.

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

R. Roussel, H. Yki-Järvinen, G. Bolli, 2015, Diabetes, obesity & metabolism.

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

R. Bergenstal, M. Riddle, G. Bolli, 2015, Diabetes, obesity and metabolism.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

P. Home, M. Riddle, G. Bolli, 2014, Diabetes Care.

Insulin Centennial: Milestones influencing the development of insulin preparations since 1922

D. Owens, G. Bolli, L. Monnier, 2021, Diabetes, obesity & metabolism.

The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications

D. Owens, G. Bolli, 2020, Diabetes, obesity & metabolism.

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)

R. Bergenstal, P. Home, M. Riddle, 2017, Diabetes, obesity & metabolism.

International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece.

D. Owens, J. Leahy, S. Garg, 2011, Diabetes technology & therapeutics.

Insulin therapy and hypoglycaemia: the size of the problem

F. Porcellati, S. Pampanelli, G. Bolli, 2004, Diabetes/metabolism research and reviews.

Enhanced stimulation of glucose uptake by insulin increases exercise-stimulated glucose uptake in skeletal muscle in humans: studies using [15O]O2, [15O]H2O, [18F]fluoro-deoxy-glucose, and positron emission tomography.

H. Sipilä, V. Oikonen, U. Ruotsalainen, 2000, Diabetes.

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal‐F1)

M. Hanefeld, G. Bolli, G. Boka, 2014, Diabetic medicine : a journal of the British Diabetic Association.

Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH

P. Lucidi, F. Porcellati, G. Bolli, 2017, Medicine.

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)

M. Matsuhisa, M. Riddle, G. Bolli, 2016, Diabetes, obesity & metabolism.

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension

R. Bergenstal, M. Riddle, H. Yki-Järvinen, 2015, Diabetes, obesity & metabolism.

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension

M. Riddle, H. Yki-Järvinen, G. Bolli, 2015, Diabetes, obesity & metabolism.

Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.

D. Owens, G. Bolli, 2008, Diabetes technology & therapeutics.

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

M. Riddle, Y. Terauchi, G. Bolli, 2016, Diabetes, obesity & metabolism.

Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes

P. Lucidi, F. Porcellati, G. Bolli, 2011, Diabetes Care.

Portal Vein Glucose Sensors Do Not Play a Major Role in Modulating Physiological Responses to Insulin-Induced Hypoglycemia in Humans

P. Lucidi, P. Rossetti, F. Porcellati, 2009, Diabetes.

Hypoglycemia, Diabetes, and Cardiovascular Events

V. Fonseca, G. Bolli, C. Desouza, 2010, Diabetes Care.

A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study

R. Roussel, H. Florez, S. Harris, 2018, Diabetes Care.

Contribution of Amino Acids and Insulin to Protein Anabolism During Meal Absorption

E. Volpi, P. Brunetti, G. Reboldi, 1996, Diabetes.

Physiology of glucose counterregulation to hypoglycemia.

G. Bolli, C. Fanelli, C. Fanelli, 1999, Endocrinology and metabolism clinics of North America.

Different Brain Responses to Hypoglycemia Induced by Equipotent Doses of the Long-Acting Insulin Analog Detemir and Human Regular Insulin in Humans

P. Rossetti, F. Porcellati, P. Candeloro, 2008, Diabetes.

Physiological insulin replacement in type 1 diabetes mellitus.

G. Bolli, 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

Acute Antihyperglycemic Mechanisms of Metformin in NIDDM: Evidence for Suppression of Lipid Oxidation and Hepatic Glucose Production

E. Ferrannini, E. Volpi, P. Brunetti, 1994, Diabetes.

Thirty Years of Research on the Dawn Phenomenon: Lessons to Optimize Blood Glucose Control in Diabetes

P. Lucidi, F. Porcellati, G. Bolli, 2013, Diabetes Care.

Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus

Paolo Rossetti, Carmine G. Fanelli, P. Rossetti, 2008 .

Insulin- and exercise-stimulated skeletal muscle blood flow and glucose uptake in obese men.

V. Oikonen, J. Knuuti, P. Nuutila, 2003, Obesity research.

utide,aWeeklyGLP -1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes

J. Rosenstock, B. Charbonnel, G. Bolli, 2013 .

Response to insulin glargine 100 U/mL treatment in newly-defined subgroups of type 2 diabetes: Post hoc pooled analysis of insulin-naïve participants from nine randomised clinical trials.

D. Owens, B. Frier, G. Bolli, 2023, Primary care diabetes.

Rational use of insulin analogues in the treatment of type 1 diabetes mellitus.

G. Bolli, Geremia B Bolli, 2003, Pediatric endocrinology reviews : PER.

Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology

P. Lucidi, F. Porcellati, G. Bolli, 2018, Current Diabetes Reports.

Insulin Infusion Set Use: European Perspectives and Recommendations

C. Cobelli, G. Charpentier, E. Renard, 2016, Diabetes technology & therapeutics.

Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.

Paolo Rossetti, P. Rossetti, F. Porcellati, 2003, Diabetes care.

Better long‐term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal‐time lispro insulin

P. Rossetti, F. Porcellati, S. Pampanelli, 2004, Diabetic medicine : a journal of the British Diabetic Association.

Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.

P. Brunetti, S. Pampanelli, G. Bolli, 1999, Diabetes care.

Strategies Toward Improved Control During Insulin Lispro Therapy in IDDM: Importance of basal insulin

P. Jansson, G. Bolli, P. Ebeling, 1997, Diabetes Care.

Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus.

P. Rossetti, F. Porcellati, G. Perriello, 2008, Archives of physiology and biochemistry.

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes

R. Bergenstal, P. Home, M. Riddle, 2016, Diabetes technology & therapeutics.

Effects of Recent, Short-Term Hyperglycemia on Responses to Hypoglycemia in Humans: Relevance to the Pathogenesis of Hypoglycemia Unawareness and Hyperglycemia-Induced Insulin Resistance

P. Brunetti, S. Pampanelli, G. Bolli, 1995, Diabetes.

Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.

R. Bergenstal, M. Riddle, G. Bolli, 2017, Diabetes & metabolism.

Evaluation of the accuracy of a microdialysis-based glucose sensor during insulin-induced hypoglycemia, its recovery, and post-hypoglycemic hyperglycemia in humans.

P. Rossetti, F. Porcellati, G. Bolli, 2006, Diabetes technology & therapeutics.

One-hundred year evolution of prandial insulin preparations: from animal pancreas extracts to rapid-ACTING analogs.

D. Owens, P. Lucidi, F. Porcellati, 2021, Metabolism: clinical and experimental.

Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women.

G. Bolli, E. Torlone, A. Gennarini, 2007, European journal of obstetrics, gynecology, and reproductive biology.

Hypoglycemia in IDDM

P. Cryer, R. Sherwin, A. Cherrington, 1989, Diabetes.

Improved Insulin Action and Glycemic Control After Long Term Angiotensin-Converting Enzyme Inhibition in Subjects with Arterial Hypertension and Type II Diabetes

P. Brunetti, G. Perriello, G. Bolli, 1993, Diabetes Care.

Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: a Double-Blind, Randomized, Crossover Study

P. Rossetti, F. Porcellati, G. Bolli, 2008, Diabetes Care.

Evidence of Increased Systemic Glucose Production and Gluconeogenesis in an Early Stage of NIDDM

E. Volpi, P. Brunetti, S. Pampanelli, 1997, Diabetes.

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

P. Lucidi, F. Porcellati, P. Candeloro, 2018, Diabetes Care.

Serum insulin and C-peptide concentration and breast cancer: a meta-analysis

P. Boyle, J. Rosenstock, P. Autier, 2013, Cancer Causes & Control.

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

P. Brunetti, F. Porcellati, S. Pampanelli, 2000, Diabetes.

Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycaemia in male and female humans

P. Brunetti, S. Pampanelli, G. Bolli, 1994, Diabetologia.

Nocturnal Blood Glucose Control in Type I Diabetes Mellitus

G. Perriello, G. Bolli, C. Fanelli, 1993, Diabetes Care.

Plasma proteomic signatures of a direct measure of insulin sensitivity in two population cohorts.

T. Assimes, L. Lazzeroni, M. Laakso, 2023, Diabetologia.

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).

M. Riddle, Y. Terauchi, G. Bolli, 2017, Diabetes & metabolism.

Less Nocturnal Hypoglycemia and Weight Gain with New Insulin Glargine 300 U/mL Compared with 100 U/mL: 1-Year Results in People with T2DM Using Basal Insulin with OADs (EDITION 2)

R. Bergenstal, M. Riddle, H. Yki-Järvinen, 2014 .

THE ROLE OF GASTRIC EMPTYING IN GLUCOSE HOMEOSTASIS AND DEFENSE AGAINST HYPOGLYCEMIA: INNOCENT BYSTANDER OR PARTNER IN CRIME?

P. Lucidi, F. Porcellati, G. Bolli, 2023, Diabetes research and clinical practice.

Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans.

E. Ghigo, P. Lucidi, P. Rossetti, 2009, The Journal of clinical endocrinology and metabolism.

Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans.

P. Rossetti, F. Porcellati, S. Pampanelli, 2003, Diabetes.

Insulin analogues and their potential in the management of diabetes mellitus

G. Bolli, V. Koivisto, G. Bolli, 1999, Diabetologia.

The dawn phenomenon in Type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity

P. De Feo, G. Perriello, G. Bolli, 2004, Diabetologia.

D. Bruttomesso, G. Bolli, E. Torlone, 2006, Diabetic medicine : a journal of the British Diabetic Association.

The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes

Hertzel C. Gerstein, J. Rosenstock, H. Gerstein, 2007, Diabetes Care.

A comparison of the effectiveness and safety of insulin glargine 300 U/ml versus 100 U/ml in children and adolescents with newly diagnosed type 1 diabetes: A retrospective, observational, short‐term study

I. Rabbone, G. Bolli, R. Bonfanti, 2022, Diabetes, obesity & metabolism.

The "dawn phenomenon"--a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus.

G. Bolli, J. Gerich, G. Bolli, 1984, The New England journal of medicine.

Use of the short‐acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time‐interval injection‐meal

P. Brunetti, S. Pampanelli, G. Perriello, 1998, Diabetic medicine : a journal of the British Diabetic Association.

Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM

P. De Feo, P. Brunetti, S. Pampanelli, 1994, Diabetologia.

Meticulous Prevention of Hypoglycemia Normalizes the Glycemic Thresholds and Magnitude of Most of Neuroendocrine Responses to, Symptoms of, and Cognitive Function During Hypoglycemia in Intensively Treated Patients With Short-Term IDDM

Paolo Brunetti, P. Brunetti, F. Porcellati, 1993, Diabetes.

Comparable efficacy with similarly low risk of hypoglycaemia in patient‐ vs physician‐managed basal insulin initiation and titration in insulin‐naïve type 2 diabetic subjects: The Italian Titration Approach Study

D. Cucinotta, A. Avogaro, G. Bolli, 2020, Diabetes/metabolism research and reviews.

Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12‐month comparison by concomitant sulphonylurea and/or glinide use

M. Riddle, Y. Terauchi, G. Bolli, 2018, Diabetes, obesity & metabolism.

Contribution of cortisol to glucose counterregulation in humans.

F Santeusanio, C Fanelli, P. Brunetti, 1989, The American journal of physiology.

Demonstration of a role for growth hormone in glucose counterregulation.

P. Brunetti, G. Perriello, G. Bolli, 1989, The American journal of physiology.

New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in Insulin-Naïve People with T2DM (EDITION 3)

R. Bergenstal, M. Riddle, G. Bolli, 2014 .

Type 1 diabetes mellitus: effective insulin strategies with less hypoglycemia.

G. Bolli, 2004, Postgraduate medicine.

Cardiovascular response to exercise in diabetic patients: influence of autonomic neuropathy of different severity

E. Puxeddu, P. Brunetti, G. Reboldi, 1995, Diabetologia.

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U / mL in People with Type 2

R. Bergenstal, P. Home, H. Yki-Järvinen, 2022 .

Reversibility of unawareness of hypoglycemia in patients with insulinomas.

P. Cryer, P. Brunetti, G. Perriello, 1993, The New England journal of medicine.

Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in Type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning

P. Brunetti, G. Perriello, G. Bolli, 2004, Diabetologia.

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin

G. Bolli, G. Bolli, F. Dotta, 2009, Diabetes, obesity & metabolism.

Modest decrements in plasma glucose concentration cause early impairment in cognitive function and later activation of glucose counterregulation in the absence of hypoglycemic symptoms in normal man.

P. Brunetti, V. Gallai†, G. Perriello, 1988, The Journal of clinical investigation.

Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24‐week, randomized, double‐blind study *

G. Bolli, G. Bolli, F. Dotta, 2007, Diabetes, obesity & metabolism.

The physiological basis of insulin therapy in people with diabetes mellitus.

P. Lucidi, F. Porcellati, G. Bolli, 2021, Diabetes research and clinical practice.

ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with Type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension

P. Brunetti, G. Perriello, G. Bolli, 1991, Diabetologia.

J. Rosenstock, R. Roussel, G. Bolli, 2018, Diabetes Care.

Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial.

P. Ponikowski, J. McMurray, J. Lewsey, 2018, JACC. Heart failure.

Gender differences in basal protein kinetics in young adults.

E. Volpi, P. Lucidi, G. Bolli, 1998, The Journal of clinical endocrinology and metabolism.

Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis.

P. Brunetti, F. Porcellati, G. Perriello, 1992, The Journal of clinical investigation.

Administration of Neutral Protamine Hagedorn Insulin at Bedtime versus with Dinner in Type 1 Diabetes Mellitus To Avoid Nocturnal Hypoglycemia and Improve Control

P. Brunetti, P. Rossetti, F. Porcellati, 2002, Annals of Internal Medicine.

Long-term intensive insulin therapy in IDDM: effects on HbA1c, risk for severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia

S. Pampanelli, G. Bolli, C. Fanelli, 1996, Diabetologia.

Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM

P. Brunetti, S. Pampanelli, G. Bolli, 1994, Diabetologia.

Rate of fall of blood glucose and physiological responses of counterregulatory hormones, clinical symptoms and cognitive function to hypoglycaemia in Type I diabetes mellitus in the postprandial state

P. Rossetti, F. Porcellati, S. Pampanelli, 2002, Diabetologia.

A Reliable and Reproducible Test for Adequate Glucose Counterregulation in Type I Diabetes Mellitus

P. Brunetti, M. M. Benedetti, G. Perriello, 1984, Diabetes.

Insulin glargine

G. Bolli, David R Owens, 2000, The Lancet.

Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus

M. Motolese, P. Brunetti, F. Porcellati, 2006, European Journal of Clinical Pharmacology.

Hypoglycemia

P. Lucidi, F. Porcellati, G. Bolli, 2019, The APRN and PA’s Complete Guide to Prescribing Drug Therapy.

Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine.

R. Becker, G. Bolli, J. Gerich, 2006, Diabetes technology & therapeutics.

Contributions of gluconeogenesis and glycogenolysis during glucose counterregulation in normal humans.

P. Cryer, G. Bolli, J. Gerich, 1989, The American journal of physiology.

Lack of glucagon response in glucose counter-regulation in Type 1 (insulin-dependent) diabetics: Absence of recovery after prolonged optimal insulin therapy

P. Brunetti, G. Calabrese, G. Bolli, 1982, Diabetologia.

Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.

G. Bolli, David R. Owens, 2008, Diabetes technology & therapeutics.

Glycemic Control and Hypoglycemia with New Insulin Glargine 300 U/mL in People with T1DM (EDITION 4)

R. Bergenstal, M. Riddle, G. Bolli, 2014 .

Sustained Glycemic Control and Less Hypoglycemia with New Insulin Glargine 300 U/mL Compared with 100 U/mL: 1-Year Results in People with T2DM Using Basal + Mealtime Insulin (EDITION 1)

Lawrence A Leiter, P. Home, M. Riddle, 2014 .

Mechanisms of glucagon secretion during insulin-induced hypoglycemia in man. Role of the beta cell and arterial hyperinsulinemia.

R. Unger, P. Brunetti, G. Perriello, 1984, The Journal of clinical investigation.

Diurnal Cycling of Insulin Sensitivity in Type 2 Diabetes: Evidence for Deviation From Physiology at an Early Stage

A. Tura, P. Lucidi, F. Porcellati, 2023, Diabetes.

Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis

G. Bolli, W. Landgraf, B. M. Frier, 2024, Diabetes therapy : research, treatment and education of diabetes and related disorders.

Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events.

A. Avogaro, P. Home, M. Riddle, 2017, Diabetes & metabolism.

Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial

B. Frier, G. Bolli, W. Landgraf, 2023, Diabetes, obesity & metabolism.

Effects of whole-body vibration exercise on the endocrine system of healthy men. J Endocrinol Invest

C. Bosco, P. Lucidi, G. Bolli, 2004 .